Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H -A. Becker

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Diabetes, Obesity & Metabolism|November 27, 2014
Low within- and between-day variability in exposure to new insulin glargine 300 U/mlR H A Becker, I Nowotny, L Teichert, et al.
Diabetologia|September 15, 2005
Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp techniqueH E Scholtz, S G Pretorius, D H Wessels, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|June 1, 2005
A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp techniqueR H A Becker, A D Frick, F Burger, et al.
Molecular & General Genetics : MGG|September 20, 1995
The binding motifs for Ac transposase are absolutely required for excision of Ds1 in maizeA M Bravo-Angel, H A Becker, R Kunze, et al.
Diabetes Care|August 24, 2014
New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1Reinhard H A Becker, Raphael Dahmen, Karin Bergmann, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|September 10, 2005
Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjectsR H A Becker, A D Frick, F Burger, et al.
Diabetes Care|August 27, 2005
Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetesThomas Danne, Reinhard H A Becker, Tim Heise, et al.
Regulatory Peptides|May 14, 2013
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemiaMartin Lorenz, Claudia Pfeiffer, Axel Steinsträsser, et al.
Diabetes, Obesity & Metabolism|December 18, 2016
Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetesChristoph Kapitza, Irene Nowotny, Anne Lehmann, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|May 20, 2008
A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetesT C Marbury, S Schwartz, M A Rosenberg, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Diabetes, Obesity & Metabolism|November 27, 2014
Low within- and between-day variability in exposure to new insulin glargine 300 U/mlR H A Becker, I Nowotny, L Teichert, et al.
Diabetologia|September 15, 2005
Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp techniqueH E Scholtz, S G Pretorius, D H Wessels, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|June 1, 2005
A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp techniqueR H A Becker, A D Frick, F Burger, et al.
Molecular & General Genetics : MGG|September 20, 1995
The binding motifs for Ac transposase are absolutely required for excision of Ds1 in maizeA M Bravo-Angel, H A Becker, R Kunze, et al.
Diabetes Care|August 24, 2014
New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1Reinhard H A Becker, Raphael Dahmen, Karin Bergmann, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|September 10, 2005
Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjectsR H A Becker, A D Frick, F Burger, et al.
Diabetes Care|August 27, 2005
Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetesThomas Danne, Reinhard H A Becker, Tim Heise, et al.
Regulatory Peptides|May 14, 2013
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemiaMartin Lorenz, Claudia Pfeiffer, Axel Steinsträsser, et al.
Diabetes, Obesity & Metabolism|December 18, 2016
Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetesChristoph Kapitza, Irene Nowotny, Anne Lehmann, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|May 20, 2008
A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetesT C Marbury, S Schwartz, M A Rosenberg, et al.
Pageof 4